Neutralization of IL-6 signaling using anti-IL-6 receptor antibodies (tocilizumab and sarilumab) or anti-IL-6 antibodies (clazakizumab) have been tested in patients with COVID-19 showing hyper-inflammation. Here, IL6 is linked to COVID-19.